Project Grant R01HL184086

The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $2,401,048 for Project Grant R01HL184086 on September 1, 2026 under the Cardiovascular Diseases Research program (CFDA 93.837).

The award funds GO MOMS PREDICT, a prospective study that develops and tests pregnancy-based cardiovascular disease risk assessment models to predict cardiovascular outcomes five years after delivery. The study leverages an existing multicenter observational cohort of 1,565 pregnant participants and analyzes cardiometabolic measures—including glycemic, lipid, and other laboratory data collected during pregnancy—to improve prediction of a composite CVD risk outcome (hypertension, prediabetes or diabetes, and hypercholesterolemia) at five years postpartum. The research uses three complementary approaches: conventional clinical testing, and additional methodologies to identify women at elevated future cardiovascular risk during obstetric care. The work aims to establish a new paradigm for cardiovascular risk assessment in pregnancy by demonstrating whether cardiometabolic measures improve prediction beyond baseline models incorporating pre-pregnancy factors and pregnancy diagnoses.

Performance occurs in Boston, Massachusetts, with a period of performance from September 1, 2026 through June 30, 2030. The assistance type is a Project Grant.